Avacta

AffyXell was established in January 2020 by Avacta and Daewoong as a joint venture to develop novel mesenchymal stem cell (MSC) therapies.

Aptuscan is a biotechnology company, develops engineered proteins for pharmaceutical, biotechnology, and diagnostic companies. The company focuses on the development of Scannins binding agents for the diagnosis and treatment of disease. Its products represent a resource for the identification of binding agents for the development of therapeutics or diagnostics, or as research reagents.

ReactivLab, Ltd. offers animal diagnostics solutions. It engages in the diagnosis and prognosis of illness based on the analysis of specific biomarker proteins. The company specializes in testing acute phase proteins, which are used as diagnostic and prognostic markers for infections, inflammation, neoplasia, and signs of trauma. The company was founded in 2007 and is based in Glasgow, United Kingdom. As of March 3, 2010, ReactivLab Ltd. operates as a subsidiary of Avacta Group Plc.

Curidium Medica identifies medicines and companion diagnostics for the treatment of central nervous system disorders.

Avacta Animal Health is an veterinary laboratory service provider and diagnostic tester to surgeons, laboratories, research & commercial organizations on animal allergies.

TheraGenetics was spun out of King's College London in April 2006. Their technology is based upon pharmacogenetics; the study of genetic factors involved in influencing an individual's response to drug treatments. The strong foundation of TheraGenetics stems from the founding team's long commitment to pharmacogenetics that has situated us at the cutting edge of personalised medicine. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the commercial world by developing the first pharmacogenetic test for response prediction in psychiatry. In 2005, this test which focuses on the schizophrenia treatment clozapine, was successfully licensed by King's College London to a major UK laboratory who have successfully brought the test to market in 2006. Based on this achievement and the overwhelming enthusiasm for personalised medicine solutions, King's College London, the academic founders and the London based venture firm IPGroup PLC launched TheraGenetics in April 2006. TheraGenetics unique knowledge and experience in CNS disorders extends from the bench to the bedside. The ultimate clinical utility has been a priority consideration at all stages of their test development; their clinical team knows what is required at the patient care interface and they develop tests accordingly. The TheraGenetic's team has a threshold of knowledge and experience spanning the whole test development process that is now allowing us to rapidly advance their work in the field of pharmacogenetic response prediction.

Oxford Medical Diagnostics develops laser-based technology for the analysis of gases. The company focuses on developing a platform for detecting minute quantities of markers in exhaled breath.